Bayer Balances a Wider Loss Against a Brighter Outlook and a Chinese First
Barrick's November 9 Reckoning: Can a Gold Tailwind Survive Contact With the P&L?
PepsiCo Bets on Holiday Shelf Space and KFC's Youth Appeal While North America Still Drags
Rheinmetall's €78 Billion Question: Can Europe's Defense Champion Convert Orders Into Revenue?
Siemens Trades Sideways as Analysts Weigh Electrification Strength Against Automation Doubts
UBS's Capital Bill Hangs on a November Vote as Cyber Risk Enters the Frame
Volkswagen Loosens Its Zero-Wage Playbook as a 1% Margin Leaves Little Room for Error
Tesla's Robot Rental Bet Meets a Wall Street Bounce
Lufthansa Clinches TAP Stake as Bernstein Flags Revenue Test for Full-Year Target
Deutsche Telekom Balances Raised Guidance With a Bigger Payout and Fresh AI Ambitions
DZ Bank Turns Bearish on Apple as New Macs Hit Shelves and a $7.5 Billion Bond Lands
OHB's November Reckoning: Can Technical Wins Translate Into Earnings?
Voestalpine Traders Weigh Deutsche Bank's EUR 63 Target Against a Softer Quarter
BASF's Buyback and Upgraded Guidance Take Centre Stage Ahead of November 23 Capital Markets Day
Palantir's Partner Wins Give the Growth Story a Factory Floor
Petrobras Plans November Diesel Imports as Refineries Run Near Capacity
Newmont's Buy Case Meets Its Toughest Test: A Cost Curve That Climbs Into 2027
Bajaj Mobility's Quarterly Profit Faces a Nine-Month Reality Check
Thyssenkrupp's Duisburg Green-Steel Plant Pushed to 2029, With Hydrogen Supply the Real Test
Leonardo's €60 Billion Backlog Faces a Two-Pronged Execution Test
Bechtle's Profit Growth Lags Revenue as Analysts Split on the Upside
Nvidia's $3 Billion Bet on Meta Comes With a Washington Asterisk
Uniper Courts Buyers With 7% Dividend Growth Pledge as Equinor Weighs Joining Brookfield Bid
Coeur Mining's Rainy River Accounting Drag Masks a Quarter of Real Cash Generation
BAT Draws Goldman Upgrade and FDA Clearance for Velo as Capital Group Slips Below 18% Stake
Erste Group Wins Private Banking Plaudits as Analysts Split on Valuation After Upgraded Outlook
BAT's C$187.5 Million Organigram Bet Lands Alongside FDA Nod for Velo and a Goldman Upgrade
Torm Locks In 53% of Fourth-Quarter Earning Days as Dividend and Newbuilds Share the Capital Bill
Ocugen's Bahamas Clearance Opens a Second Clock, With OCU400 Data Still the Judge
Vistra Backs Raised Guidance With $1.5 Billion Buyback Authorization
Nestlé Backs Full-Year Targets as Ski Sponsorship and U.S. Plant Shift Reshape the Story
SoftBank's November Reckoning: Can the Balance Sheet Carry the AI Vision?